Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Reaffirmed by William Blair

William Blair restated their outperform rating on shares of Neumora Therapeutics (NASDAQ:NMRAFree Report) in a research note issued to investors on Friday, RTT News reports.

Other analysts have also recently issued reports about the company. Royal Bank of Canada reiterated an outperform rating and set a $31.00 price target on shares of Neumora Therapeutics in a research report on Thursday, March 28th. JPMorgan Chase & Co. increased their price target on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an overweight rating in a research report on Monday, March 18th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics has an average rating of Moderate Buy and an average target price of $22.57.

Read Our Latest Analysis on Neumora Therapeutics

Neumora Therapeutics Stock Down 3.2 %

NASDAQ:NMRA opened at $13.56 on Friday. The business’s 50 day moving average is $16.14 and its two-hundred day moving average is $14.20. Neumora Therapeutics has a 52 week low of $9.35 and a 52 week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRAGet Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.05. As a group, equities analysts expect that Neumora Therapeutics will post -1.48 EPS for the current year.

Institutional Trading of Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank acquired a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $29,000. California State Teachers Retirement System acquired a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $42,000. Tower Research Capital LLC TRC acquired a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $44,000. Strs Ohio acquired a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $54,000. Finally, SG Americas Securities LLC acquired a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $108,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

(Get Free Report)

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Read More

Analyst Recommendations for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.